Integral Diagnostics Announces FY26 Financial Results Release and Investor Conference Call Scheduled for August 25, 2026

Integral Diagnostics' Leading Role in Australasian Medical Imaging Services

Integral Diagnostics Limited holds a leading position in delivering medical imaging services across Australia and New Zealand, establishing itself as a key participant in the diagnostic healthcare sector. The company’s business model revolves around providing diagnostic imaging through a widespread network of facilities and expert practitioners in the region. IDX differentiates itself by employing Australasia’s foremost radiologists and diagnostic imaging specialists, underscoring its dedication to clinical excellence.

Operating across two significant Asia-Pacific markets, IDX offers medical imaging services to patients and healthcare providers in both countries. This geographic diversification exposes the company to two advanced healthcare systems with robust demand for diagnostic services. IDX’s status as a "leading provider" highlights its established market presence and competitive edge within the medical imaging industry. The company emphasizes its clinical leadership and specialist team as fundamental competitive advantages in delivering superior patient care and service quality.

IDX’s Distinctive Medical Leadership Operating Framework

A notable aspect of Integral Diagnostics’ operational strategy is its unique medical leadership model. This approach prioritizes physician leadership and active involvement in business strategy, differing from traditional healthcare service structures. By positioning radiologists and diagnostic imaging specialists in leadership roles, IDX aligns clinical expertise with business decision-making. The company asserts this model ensures high-quality patient care, efficient service delivery, and broad access to diagnostic services across its network.

This medical leadership philosophy reflects current trends in healthcare management where clinicians play key roles in governance and strategic planning. The structure aims to keep clinical priorities, patient outcomes, and service standards at the forefront of operations rather than subordinated to financial goals. IDX’s motto, "good medicine is good business," encapsulates this belief that excellent clinical outcomes and patient care foster sustainable business success. This operational distinction may be significant for institutional investors assessing management quality and organisational alignment within healthcare providers.

FY26 Results Release Schedule and Investor Participation Information

Integral Diagnostics has confirmed the full-year FY26 results will be published on the morning of Tuesday, 25 August 2026. This timing follows the fiscal year-end and allows for audit completion and regulatory filings. The announcement will be immediately followed by a group investor conference call, enabling investors and analysts to receive management commentary and guidance promptly after the financial results release. This same-day format facilitates timely access to strategic insights and management perspectives.

The investor conference call is scheduled for 11:00am AEST, accommodating participants across Australian and New Zealand time zones. IDX offers multiple access options to suit investor preferences, including an online registration portal and traditional telephone dial-in. Conference ID 10056165 is required for phone participants. The company notes potential wait times during peak call periods, common in large investor calls. Providing both online and phone access ensures broad accessibility for IDX’s investor base across regions and technical preferences.

Investor Online Registration and Telephone Dial-In Details

Investors interested in joining the Integral Diagnostics investor conference call on 25 August 2026 can register online via the dedicated link: https://s1.c-conf.com/diamondpass/10056165-zch721.html. Online registration streamlines access to the webcast and allows receipt of supplementary materials or updates related to the presentation. This method is standard in investor relations, enabling the company to manage attendee information and communicate follow-ups efficiently.

For those preferring telephone access, IDX provides dedicated dial-in numbers for Australian and New Zealand investors. Australian participants can call 1800 809 971 (toll-free) or 02 9007 3187 (Sydney local). New Zealand investors may dial 0800 453 055 (toll-free) or +64 9 929 1687 (Auckland local). All phone participants must use conference ID 10056165 to join. IDX advises that wait times may occur due to high call volumes typical of publicly listed company results calls. This multi-channel access approach reflects best practices in investor relations, minimizing participation barriers for shareholders.

Investor Contact Information for Further Assistance

Integral Diagnostics has appointed John Merity, Company Secretary, as the primary contact for investor inquiries regarding the FY26 results release and conference call logistics. He can be reached at 0418 817 255 or via email at [email protected]. Providing a direct contact supports investors needing clarification on registration, technical issues, or logistical questions related to the conference call.

Additional investor relations resources are available on the company’s website at www.integraldiagnostics.com.au, which hosts announcements, financial reports, and corporate updates. IDX’s head office is located at Level 2, 288 Victoria Parade, East Melbourne, Victoria 3002, with postal correspondence directed to PO Box 551, East Melbourne, VIC 8002. General enquiries can be made via [email protected] or by phone at +61 3 5339 0704. This multi-channel communication strategy ensures investors can connect through their preferred methods and reach appropriate company representatives.

Importance of FY26 Financial Results for Stakeholders

The FY26 financial results release is a pivotal event for investors evaluating Integral Diagnostics’ financial health, operational performance, and strategic direction. Full-year disclosures typically include audited financial statements, management analysis of market conditions and operational results, and forward-looking guidance when appropriate. Investors will scrutinize metrics such as revenue, utilisation rates of imaging facilities, pricing trends, staffing, and capital investments in imaging technology and facility expansion.

The investor conference call offers management a platform to contextualize financial outcomes within broader industry trends, including diagnostic imaging demand, competitive dynamics, and ongoing strategic initiatives. Analysts will update financial models and investment theses based on this information, while institutional investors will assess alignment with prior guidance and projections. The immediate post-results dialogue aims to enhance market efficiency and reduce information asymmetry between management and investors. This structured disclosure and engagement approach aligns with ASX listing requirements and best practices.

Future Reporting and Investor Engagement Timeline

The FY26 results release and conference call mark a key event in IDX’s 2026 investor relations calendar. Following the August announcement, investors can anticipate subsequent disclosures such as interim FY27 results, trading updates, capital management news, or strategic developments. The ASX-listed company reporting cycle typically includes full-year results in August or September for June year-end companies, followed by interim results around February, providing regular communication touchpoints.

IDX’s commitment to hosting a dedicated investor call immediately after results publication demonstrates a robust approach to capital market engagement. Offering both online and telephone participation caters to diverse investor preferences and accessibility needs. For current and prospective investors, the FY26 results presentation on 25 August 2026 will be the primary source of audited financial data and management commentary on the company’s FY26 performance. Subsequent disclosures will continue in accordance with ASX regulations.

Healthcare Sector Trends and Diagnostic Imaging Demand Drivers

Integral Diagnostics operates within the healthcare services sector, focusing on medical imaging and diagnostic services essential to modern healthcare delivery. Diagnostic imaging modalities such as X-ray, CT, MRI, ultrasound, and related procedures are critical for diagnosis, treatment planning, and patient management in Australia and New Zealand. Demand drivers include population growth, aging demographics, chronic disease prevalence, healthcare expenditure patterns, and clinical guidelines influencing imaging utilisation.

The medical imaging sector in Australia and New Zealand functions within regulated environments overseen by professional bodies, clinical colleges, and accreditation agencies that maintain imaging standards and radiologist qualifications. Both countries feature sophisticated healthcare systems with public and private components. Diagnostic imaging is delivered through hospitals, private centres, and integrated networks, creating a competitive and diverse market. IDX’s leadership and extensive network position it to capitalize on sustained demand across multiple markets and patient segments. Industry trends such as technological innovation, increasing diagnostic complexity, and rising chronic disease rates support ongoing growth prospects for imaging services and IDX’s business trajectory.